SQZ Biotechnologies Price to Sales Ratio 2020-2022 | SQZ

Historical PS ratio values for SQZ Biotechnologies (SQZ) over the last 10 years. The current P/S ratio for SQZ Biotechnologies as of February 03, 2023 is . For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide.
SQZ Biotechnologies P/S Ratio Historical Data
Date Stock Price TTM Sales per Share Price to Sales Ratio
2023-02-03 0.82 1.05
2022-09-30 2.28 $0.78 2.92
2022-06-30 3.18 $0.83 3.82
2022-03-31 4.81 $0.88 5.45
2021-12-31 8.93 $0.99 9.04
2021-09-30 14.42 $1.00 14.42
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.023B $0.027B
SQZ Biotechnologies Company is a clinical-stage biotechnology company. It develops transformative cell therapies for patients with cancer, infectious diseases and other serious conditions. The company's prime product candidate consist SQZ-PBMC-HPV which is in clinical stage. SQZ Biotechnologies Company is based In Watertown, Massachusetts.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $154.721B 9.45
GSK (GSK) United Kingdom $71.915B 9.49
Bio-Rad Laboratories (BIO.B) United States $12.069B 28.64
QIAGEN (QGEN) Netherlands $11.215B 19.14
Ginkgo Bioworks Holdings (DNA) United States $4.249B 0.00
Myovant Sciences (MYOV) United Kingdom $2.615B 0.00
Arcus Biosciences (RCUS) United States $1.532B 23.00
Biohaven (BHVN) United States $1.307B 0.00
Emergent Biosolutions (EBS) United States $0.726B 5.71
ADC Therapeutics SA (ADCT) Switzerland $0.376B 0.00
Ambrx Biopharma (AMAM) United States $0.071B 0.00
Enzo Biochem (ENZ) United States $0.067B 0.00
Gelesis Holdings (GLS) United States $0.022B 0.00